SAGE Sage Therapeutics Inc

Price (delayed)

$33.62

Market cap

$1.99B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.22

Enterprise value

$1.82B

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing ...

Highlights
The company's debt fell by 26% YoY and by 8% QoQ
SAGE's quick ratio is down by 35% YoY but it is up by 2.5% QoQ
The net income has dropped by 176% year-on-year and by 6% since the previous quarter
Sage Therapeutics's EPS has plunged by 166% YoY and by 5% from the previous quarter

Key stats

What are the main financial stats of SAGE
Market
Shares outstanding
59.07M
Market cap
$1.99B
Enterprise value
$1.82B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.23
Price to sales (P/S)
314.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
289.01
Earnings
Revenue
$6.31M
EBIT
-$484.18M
EBITDA
-$482.31M
Free cash flow
-$377.44M
Per share
EPS
-$8.22
Free cash flow per share
-$6.39
Book value per share
$27.41
Revenue per share
$0.11
TBVPS
$28.9
Balance sheet
Total assets
$1.71B
Total liabilities
$87.2M
Debt
$16.92M
Equity
$1.62B
Working capital
$1.6B
Liquidity
Debt to equity
0.01
Current ratio
21.65
Quick ratio
21.19
Net debt/EBITDA
0.34
Margins
EBITDA margin
-7,647.2%
Gross margin
89.7%
Net margin
-7,676.9%
Operating margin
-7,731.1%
Efficiency
Return on assets
-25.9%
Return on equity
-27.2%
Return on invested capital
-33.3%
Return on capital employed
-29.7%
Return on sales
-7,676.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SAGE stock price

How has the Sage Therapeutics stock price performed over time
Intraday
-5.24%
1 week
-0.71%
1 month
4.93%
1 year
-41.03%
YTD
-20.97%
QTD
1.57%

Financial performance

How have Sage Therapeutics's revenue and profit performed over time
Revenue
$6.31M
Gross profit
$5.66M
Operating income
-$487.6M
Net income
-$484.18M
Gross margin
89.7%
Net margin
-7,676.9%
Sage Therapeutics's operating income has plunged by 177% YoY and by 6% from the previous quarter
The net income has dropped by 176% year-on-year and by 6% since the previous quarter
The revenue has plunged by 99% YoY
The company's gross profit has shrunk by 99% YoY

Growth

What is Sage Therapeutics's growth rate over time

Valuation

What is Sage Therapeutics stock price valuation
P/E
N/A
P/B
1.23
P/S
314.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
289.01
Sage Therapeutics's EPS has plunged by 166% YoY and by 5% from the previous quarter
The P/B is 76% less than the 5-year quarterly average of 5.3 and 14% less than the last 4 quarters average of 1.5
SAGE's equity is down by 19% YoY and by 6% from the previous quarter
The revenue has plunged by 99% YoY
SAGE's P/S is 87% above its last 4 quarters average of 177.7 but 45% below its 5-year quarterly average of 602.3

Efficiency

How efficient is Sage Therapeutics business performance
SAGE's ROA has dropped by 159% year-on-year and by 11% since the previous quarter
Sage Therapeutics's ROE has plunged by 158% YoY and by 11% from the previous quarter
The ROIC has plunged by 135% YoY
Sage Therapeutics's ROS has decreased by 6% from the previous quarter

Dividends

What is SAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SAGE.

Financial health

How did Sage Therapeutics financials performed over time
SAGE's quick ratio is down by 35% YoY but it is up by 2.5% QoQ
The current ratio has contracted by 35% YoY but it has grown by 2.4% from the previous quarter
The company's debt is 99% lower than its equity
The company's debt fell by 26% YoY and by 8% QoQ
SAGE's equity is down by 19% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.